Copyright
©The Author(s) 2016.
World J Pharmacol. Jun 9, 2016; 5(2): 51-58
Published online Jun 9, 2016. doi: 10.5497/wjp.v5.i2.51
Published online Jun 9, 2016. doi: 10.5497/wjp.v5.i2.51
Serotonergic drugs | Mode of action | Compound AP |
Serotonin (10-20 μmol/L) | Agonist | Increased |
Fluoxetine (10 μmol/L) | SSRI | Increased |
m-CPBG (1 μmol/L) | Receptor agonist | Increased |
Tropisetron (5 μmol/L) | Receptor antagonist | Reduced |
Ondansetron (5 μmol/L) | Receptor antagonist | Reduced |
MDL 72222 (0.5 μmol/L) | Receptor antagonist | Reduced |
Reserpine pretreatment (3 mg/kg) | 5-HT3 depletion | No gLTP |
m-CPBG (1 μmol/L) + reserpine | Receptor agonist | Increased |
- Citation: Alkadhi KA. Long-term potentiation in autonomic ganglia: Potential role in cardiovascular disorders. World J Pharmacol 2016; 5(2): 51-58
- URL: https://www.wjgnet.com/2220-3192/full/v5/i2/51.htm
- DOI: https://dx.doi.org/10.5497/wjp.v5.i2.51